SkinBioTherapeutics (LON:SBTX) Announces Quarterly Earnings Results

SkinBioTherapeutics (LON:SBTX) issued its quarterly earnings results on Wednesday. The company reported GBX (0.46) (($0.01)) earnings per share for the quarter, Digital Look Earnings reports. SkinBioTherapeutics had a negative net margin of 237.95% and a negative return on equity of 115.86%.

SkinBioTherapeutics Stock Performance

Shares of SBTX opened at GBX 24.20 ($0.31) on Friday. SkinBioTherapeutics has a 52 week low of GBX 8.32 ($0.11) and a 52 week high of GBX 26.45 ($0.34). The company has a debt-to-equity ratio of 27.57, a quick ratio of 10.01 and a current ratio of 0.93. The company has a market capitalization of £55.28 million, a PE ratio of -14.88 and a beta of 2.01. The company’s 50 day moving average price is GBX 20.16 and its 200 day moving average price is GBX 16.70.

SkinBioTherapeutics Company Profile

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.